Eikon Therapeutics, Inc. (EIKN)
NASDAQ: EIKN · Real-Time Price · USD
9.36
+0.42 (4.70%)
At close: Sep 14, 2026, 4:00 PM EDT
9.35
-0.01 (-0.16%)
After-hours: Sep 14, 2026, 7:30 PM EDT
Eikon Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Four clinical-stage drug candidates are advancing, including two highly selective PARP1 inhibitors with reduced toxicity and a TLR7/8 agonist in late-stage trials. Proprietary imaging technology accelerates drug discovery and supports expansion into new therapeutic areas. Cash reserves of $531.2 million support ongoing studies.
-
PARP1-selective inhibitors are positioned to address the hematologic toxicity of first-gen PARP inhibitors, enabling higher dosing, longer treatment, and more combination options. Eikon's clinical programs show promising early safety and efficacy, with key data to be presented at ESMO. Werner helicase inhibitors offer a new approach for MSI tumors, emphasizing disease control and tolerability.